Protection of IFNAR (-/-) mice against bluetongue virus serotype 8, by heterologous (DNA/rMVA) and homologous (rMVA/rMVA) vaccination, expressing outer-capsid protein VP2.
The protective efficacy of recombinant vaccines expressing serotype 8 bluetongue virus (BTV-8) capsid proteins was tested in a mouse model. The recombinant vaccines comprised plasmid DNA or Modified Vaccinia Ankara viruses encoding BTV VP2, VP5 or VP7 proteins. These constructs were administered alo...
Main Authors: | Tamara Kusay Jabbar, Eva Calvo-Pinilla, Francisco Mateos, Simon Gubbins, Abdelghani Bin-Tarif, Katarzyna Bachanek-Bankowska, Oya Alpar, Javier Ortego, Haru-Hisa Takamatsu, Peter Paul Clement Mertens, Javier Castillo-Olivares |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2013-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3625202?pdf=render |
Similar Items
-
Significant protection from infection and AIDS progression after gastrointestinal and oral vaccinations, respectively, with a SIV DNA/rMVA vaccine
by: Aldovini A, et al.
Published: (2012-09-01) -
Heterologous prime-boost regimens using rAd35 and rMVA vectors elicit stronger cellular immune responses to HIV proteins than homologous regimens.
by: Silvia Ratto-Kim, et al.
Published: (2012-01-01) -
Detection of broad functional gag-specific CD4+T cell responses in HIV-1-infected subjects following therapeutic immunization with rMVA expressing an HIV-1 gag immunogen
by: Ondondo, B, et al.
Published: (2006) -
Detection of broad functional gag-specific CD4+ T cell responses in HIV-1-infected subjects following therapeutic immunization with rMVA expressing an HIV-1 gag immunogen
by: Rowland-Jones Sarah L, et al.
Published: (2006-12-01) -
A modified vaccinia Ankara virus (MVA) vaccine expressing African horse sickness virus (AHSV) VP2 protects against AHSV challenge in an IFNAR -/- mouse model.
by: Javier Castillo-Olivares, et al.
Published: (2011-01-01)